GMP IPO Watch
Tata Nifty MidSmall Healthcare Index Fund
Direct Plan · Growth Option · Tata Mutual Fund
Returns
Annualised (CAGR) returns for periods over a year.
Want to invest in this fund?
Open a free demat & trading account with Zerodha to invest in direct mutual funds with zero commission.
Rank in Category
| Period | This Fund | Category Avg. | Rank |
|---|---|---|---|
| 1W | +3.35% | +3.19% | 160 of 283 |
| 1M | +3.20% | +2.85% | 112 of 283 |
| 3M | +1.44% | -2.37% | 34 of 283 |
| 6M | +14.63% | +1.56% | 4 of 278 |
| YTD | +19.80% | -0.86% | 2 of 283 |
| 1Y | +17.94% | -0.15% | 6 of 263 |
| 2Y | +10.69% | +2.58% | 7 of 193 |
| INCEPTION | +18.48% | — | — |
Ranked among: Other Scheme - Index Funds.
Rolling Returns
| Period | Average | Best | Worst | Positive Periods | Consistency |
|---|---|---|---|---|---|
| 3M | +4.76% | +27.69% | -14.55% | 66% | 27% |
| 6M | +7.71% | +31.14% | -11.49% | 68% | 28% |
| 1Y | +11.65% | +25.83% | -2.04% | 95% | 41% |
| 2Y | +14.31% | +20.31% | +6.99% | 100% | 45% |
Rolling returns show the average, best and worst outcome an investor would have seen entering at any point in the window.
NAV History
AUM Trend (₹ Cr, quarterly average)
Expense Ratio Trend
Portfolio · Sep 2026
Asset Allocation
- Equity100.14%
- Debt0.00%
- Cash-0.14%
- Other0.00%
Market Cap Split
- Large Cap0.00%
- Mid Cap67.82%
- Small Cap32.18%
- Others0.00%
Fundamentals
| Fund | Category | |
|---|---|---|
| P/E | 38.74 | 23.30 |
| P/B | 5.47 | 3.81 |
| Price / Sales | 5.61 | 3.27 |
| Price / Cash Flow | 27.22 | 17.22 |
| Dividend Yield (%) | 0.41 | 1.63 |
Holdings · Sep 2026
| Holding | Sector | Weight | Change (1M) |
|---|---|---|---|
| Laurus Labs | Pharmaceuticals & Biotechnology | 11.84% | +0.62% |
| Lupin | Pharmaceuticals & Biotechnology | 7.57% | -0.44% |
| Aurobindo Pharma | Pharmaceuticals & Biotechnology | 7.09% | -0.07% |
| Fortis Healthcare | Equity | 6.16% | -0.96% |
| Glenmark Pharmaceuticals | Pharmaceuticals & Biotechnology | 5.40% | -0.22% |
| Alkem Laboratories | Pharmaceuticals & Biotechnology | 4.78% | +0.08% |
| Mankind Pharma | Pharmaceuticals & Biotechnology | 4.36% | +0.23% |
| IPCA Laboratories | Pharmaceuticals & Biotechnology | 4.11% | -0.02% |
| Biocon | Pharmaceuticals & Biotechnology | 3.96% | -0.47% |
| Gland Pharma | Pharmaceuticals & Biotechnology | 3.55% | +0.09% |
| Sai Life Sciences | Pharmaceuticals & Biotechnology | 3.24% | +0.21% |
| Krishna Institute of Medical Sciences | Equity | 3.06% | +0.11% |
| Aster DM Quality Care | Equity | 2.86% | -0.02% |
| Neuland Laboratories | Pharmaceuticals & Biotechnology | 2.83% | -0.16% |
| Wockhardt | Pharmaceuticals & Biotechnology | 2.68% | +0.34% |
View all 32 holdings
| Acutaas Chemicals | Pharmaceuticals & Biotechnology | 2.61% | +0.14% |
| Ajanta Pharma | Pharmaceuticals & Biotechnology | 2.53% | +0.24% |
| Dr. Lal Path Labs | Equity | 2.38% | +0.11% |
| Abbott | Pharmaceuticals & Biotechnology | 2.17% | +0.14% |
| Piramal Pharma | Pharmaceuticals & Biotechnology | 1.97% | -0.04% |
| Granules | Pharmaceuticals & Biotechnology | 1.92% | +0.11% |
| Narayana Hrudayalaya | Equity | 1.90% | -0.08% |
| Global Health | Equity | 1.86% | -0.05% |
| Onesource Specialty Pharma | Pharmaceuticals & Biotechnology | 1.84% | +0.04% |
| GlaxoSmithKline Pharmaceuticals | Pharmaceuticals & Biotechnology | 1.76% | -0.14% |
| Anthem Biosciences | Pharmaceuticals & Biotechnology | 1.42% | — |
| Natco Pharma | Pharmaceuticals & Biotechnology | 1.14% | +0.00% |
| Cohance Lifesciences | Pharmaceuticals & Biotechnology | 1.11% | -0.01% |
| Syngene International | Equity | 1.06% | -0.09% |
| Poly Medicure | Equity | 0.98% | -0.03% |
| I) REPO | Reverse Repo / TREPS | 0.13% | — |
| NET CURRENT LIABILITIES | Net Current Assets | -0.27% | — |
Sector Allocation · Sep 2026
Risk Metrics
Standard Deviation
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 15.34 | 12.38 | High Volatility |
What is this?
Annualized population standard deviation of daily denomination-adjusted NAV returns, multiplied by sqrt(252). Values require a full timeframe of NAV history.
Sharpe Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 0.82 | -0.51 | Above Average |
| 3Y | 0.75 | 0.26 | Above Average |
What is this?
Annualized Sharpe ratio calculated from month-end NAV returns using the latest available FBIL Overnight MIBOR rate as the risk-free rate. For schemes with less than three years of history, the 3Y value uses since-inception data. Applied risk-free rate: 5.73% (published 2026-10-28).
Sortino Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 1.77 | 12.56 | Below Average |
What is this?
Annualized from daily NAV returns using a 0.00% minimum acceptable return; downside deviation includes only returns below this target.
Tracking Difference
Versus Nifty MidSmall Healthcare TRI, as of Sep 2026.
Compare With Peers
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
ICICI Prudential Nifty Pharma Index Fund
Direct Plan · IDCW
|
+22.53% | +22.50% | — | +21.44% |
|
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund
Direct Plan · Growth
|
+20.88% | +21.50% | +14.91% | +16.74% |
|
Tata Nifty Capital Markets Index Fund
Direct Plan · Growth Option
|
+19.89% | — | — | +21.71% |
|
Motilal Oswal Nifty Capital Market Index Fund
Regular Plan · Growth
|
+19.31% | — | — | +16.06% |
|
Motilal Oswal S&P 500 Index Fund
Direct Plan · GROWTH
|
+18.19% | +25.74% | +16.20% | +20.46% |
|
Motilal Oswal Nifty MidSmall Healthcare Index Fund
Regular Plan · Growth
|
+17.19% | — | — | +11.55% |
|
ICICI Prudential NASDAQ 100 Index Fund
Regular Plan · Growth
|
+15.21% | +27.99% | +16.74% | +17.49% |
|
Bandhan BSE Healthcare Index Fund
Regular Plan · Growth
|
+13.22% | — | — | +7.26% |
|
Motilal Oswal Nifty India Defence Index Fund
Regular Plan · Growth
|
+13.06% | — | — | +4.19% |
|
DSP Nifty Healthcare Index Fund
Regular Plan · Growth
|
+12.65% | — | — | +12.61% |
More From Tata Asset Management Private Limited
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
| Tata Silver Exchange Traded Fund | +26.44% | — | — | +39.36% |
|
Tata Silver ETF Fund of Fund
Direct Plan · IDCW Reinvestment Option
|
+25.50% | — | — | +37.64% |
|
Tata Nifty Capital Markets Index Fund
Direct Plan · IDCW Payout Option
|
+19.89% | — | — | +21.71% |
| Tata Gold Exchange Traded Fund | +16.49% | — | — | +32.90% |
|
Tata Gold ETF Fund of Fund
Direct Plan · IDCW Reinvestment Option
|
+16.32% | — | — | +31.66% |
|
Tata Ultra Short Term Fund
Direct Plan · Monthly Reinvestment of Income Distribution cum capital withdrawal option
|
+6.91% | +7.27% | +6.74% | +6.49% |
|
Tata Arbitrage Fund
Direct Plan · Monthly Payout of Income Distribution cum capital withdrawal option
|
+6.71% | +7.42% | +6.95% | +5.88% |
|
Tata India Pharma & Healthcare Fund
Direct Plan · Growth Option
|
+6.67% | +19.61% | +15.20% | +13.24% |
|
Tata Money Market Fund
Direct Plan · Growth Option
|
+6.49% | +7.44% | +6.90% | +6.76% |
|
Tata Liquid Fund
Direct Plan · Growth Option
|
+6.48% | +6.92% | +6.43% | +6.86% |
About This Scheme
Investment Objective
The investment objective of the scheme is to provide returns, before expenses, that are in line with the performance of Nifty MidSmall Healthcare Index (TRI), subject to tracking error. However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved. The scheme does not assure or guarantee any returns
Stated Asset Allocation
Securities covered by Nifty MidSmall HealthcareIndex (95-100),Debt & Money Market Instruments^ including units of Mutual Funds (0-5). The scheme can invest residual portion of upto 5% in other liquid instruments** in addition to the existing instruments mentioned in the offer documents. **Other liquid instruments include cash, bank deposits with Scheduled Commercial Banks, Government Securities, Treasury bills, Repo on Government securities and any other instruments as specified by the SEBI.
Exit Load
0.25% of the applicable NAV, if redeemed on or before 15 days from the date of allotment.
Fund Managers
1. Nitin Sharma, 2. Rakesh Prajapati
1. Nitin Sharma - Primary, 2. Rakesh Prajapati - Assistant Fund Manager
Mutual fund investments are subject to market risks. Read all scheme related documents carefully. Past performance is not indicative of future returns. Data is sourced from AMFI and fund houses via FinAPI and may lag official figures.